LRP5 and diabetes mellitus: Recently, semaglutide, a GLP1 receptor agonist frequently used in diabetes, has shown promising effects in the osteogenic differentiation of bone marrow stem cells via Wnt/LRP5/β-catenin signaling pathway activation in in vitro studies, and there is a need for in vivo studies to confirm this effect [83].